January 20, 2020
Precigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T™ in Patients With Acute Myeloid Leukemia (AML) – BioHealth Capital Region
GERMANTOWN, Md., Jan. 6, 2020 /PRNewswire/ — Precigen, Inc., a biopharmaceutical company specializing in the development of…
